ArticleNucleic acids research2026
Novel intermolecular zinc fingers and redox-driven conformational changes dictate tumor suppressor ZMYND11's role in cooperative recognition of diverse targets.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding ZMYND11-Related Syndromic Intellectual Disability: From Epigenetic Mysteries to Therapeutic Horizons.Neuroscience bulletin · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The zinc finger-myeloid-Nervy-DEAF-1 (ZMYND) protein family is associated with embryonic development and cancer regulation. Specifically, the tumor suppressor ZMYND11 is downregulated in multiple malignancies. Here, we identified an inhibitory role of ZMYND11 in colorectal cancers and determined crystal structures of the winged helix domain (WH), a plant homeodomain (PHD), coiled-coil-MYND (CC-MYND) domains, and their complex with an adenovirus E1A peptide. Unexpectedly, intermolecular zinc finger and intermolecular disulfide bonds were found for domains PHD and WH/CC-MYND, respectively. Interestingly, the oligomeric state of the PHD domain was pH-dependent, and the redox state of the CC domain impaired the binding, such as in the tumor or inflammatory microenvironments. Moreover, these conformational flexibilities facilitated ZMYND11 to bind diverse substrates. Comprehensive analysis and multiple assays showed that the Bromo-PWWP domains cooperate with the WH domain and the PHD domain to bind nucleic acids and histones, respectively. Thus, ZMYND11 is pivotal in chromatin binding and gene regulation, and may critically influence the expression of tumor-associated genes. Furthermore, both PHD and CC-MYND domains interact with the nucleic acid repair protein ALKBH6, revealing a previously uncharacterized epigenetic mechanism. Overall, these novel characteristics enable ZMYND11 as a global tumor suppressor to accommodate many substrates, thereby providing the structural basis for its broad recognition mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.